Candela

Candela Launches Exceed Microneedling System in U.S.

Candela To Commercialize MT.DERM Systems

Candela Corporation is now offering the Exceed Microneedling device for the treatment of wrinkles and facial acne scars. The company recently entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of its medical microneedling products. Under the terms of the agreement, Candela will commercialize the Exceed medical microneedling system globally, with an initial launch in the United States. The agreement may be expanded with additional products in the future.

Syneron-Candela Is Now Candela

Syneron-Candela, a global medical aesthetic device company, has rebranded the company to Candela and unveiled its new corporate branding at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington DC, on March 1. The new corporate identity reflects the unification of the Syneron and Candela brands and is designed to support continued global market growth as a unified single entity.

FDA Clears Vbeam Prima PDL for Sale in the U.S.

New and Improved PDL from Candela

The U.S. Food and Drug Administration (FDA) has cleared Candela Corporation’s Vbeam Prima, an advanced 595nm pulsed dye laser (PDL) with an additional 1,064nm wavelength, for marketing in the United States. In addition to the added 1,064nm wavelength, the VBeam Prima offers a number of other new features to more effectively treat a broad range of skin conditions, including rosacea, port wine stains, acne, facial, leg and spider veins, scars, benign pigmented lesions and wrinkles, warts, stretch marks and photo aging.